cyteir

About cyteir

This author has not yet filled in any details.
So far cyteir has created 11 blog entries.

Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program

2021-02-11T08:23:35-05:00

Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program Proceeds will support monotherapy and combination therapy trials of first-in-class RAD51 inhibitor CYT-0851, as well as fund R&D for novel synthetic lethal cancer targets The round, led by RA Capital Management, was joined by other leading public [...]

Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program2021-02-11T08:23:35-05:00

Cyteir Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

2021-01-07T12:43:56-05:00

Cyteir Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference LEXINGTON, Mass., January 7, 2021 – Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies to treat cancer, today announced that Markus Renschler, M.D., Cyteir’s president and chief executive officer, will present a scientific and business update [...]

Cyteir Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference2021-01-07T12:43:56-05:00

Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team

2020-07-07T13:09:13-04:00

Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team Phase 1/2 study of first-in-class inhibitor of RAD51-mediated homologous recombination advancing to once-daily dosing Secrist, Gengos and Englert join Cyteir leadership team, enhancing company’s scientific, strategic business development, and drug development expertise LEXINGTON, Mass., July 7, [...]

Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team2020-07-07T13:09:13-04:00

Cyteir Therapeutics Secures Additional $40.2 Million in its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor

2019-10-14T15:57:19-04:00

Cyteir Therapeutics Secures Additional $40.2 Million in its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor New funding brings total Series B raise to $75.2 million Novo Holdings led round, joined by Venrock, DROIA, Osage University Partners, Lightstone and Celgene Corporation RAD51 inhibitor CYT-0851 now being evaluated [...]

Cyteir Therapeutics Secures Additional $40.2 Million in its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor2019-10-14T15:57:19-04:00

Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors

2019-04-01T14:12:34-04:00

Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors Novel, targeted, oral drug candidate inhibits DNA-repair protein to induce cell death in multiple cancer types including pancreatic cancer and B-cell non-Hodgkin lymphoma Preclinical data suggest CYT-0851 may overcome resistance to PARP inhibitors Data [...]

Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors2019-04-01T14:12:34-04:00

Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases

2018-03-08T12:03:05-05:00

Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases Lead investor Venrock joined by Celgene, Lightstone and DROIA Markus Renschler, M.D., joins as CEO, from Celgene Financing proceeds will be used to advance RAD51 inhibitor toward the clinic and expand small-molecule synthetic lethality platform for [...]

Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases2018-03-08T12:03:05-05:00

Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice from Type 1 Diabetes (T1D)

2018-03-07T22:46:39-05:00

Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice from Type 1 Diabetes (T1D)  --Data demonstrates that therapeutic targeting of the AID/RAD51 axis in B cells may block development of T1D by converting B cells to a suppressive population capable of inhibiting disease development --  --First demonstration of synthetic lethal pairs in a [...]

Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice from Type 1 Diabetes (T1D)2018-03-07T22:46:39-05:00

Cyteir Therapeutics Presents Preclinical Data Validating RAD51-AID as a Novel Target for Cancer Treatment at American Association of Cancer Research Annual Meeting

2018-03-07T22:46:02-05:00

Cyteir Therapeutics Presents Preclinical Data Validating RAD51-AID as a Novel Target for Cancer Treatment at American Association of Cancer Research Annual Meeting  -- Preclinical data elucidates mechanism and demonstrates successful intervention with small molecules in leukemia and lymphoid cancer models --   -- Clinical candidate expected to be identified in 2017 --  CAMBRIDGE, Mass. – March 28, [...]

Cyteir Therapeutics Presents Preclinical Data Validating RAD51-AID as a Novel Target for Cancer Treatment at American Association of Cancer Research Annual Meeting2018-03-07T22:46:02-05:00

Cyteir Therapeutics Presents Preclinical Data on Use of DNA Repair Modulators for Lymphoid Malignancies at American Society of Hematology Annual Meeting

2018-03-07T22:47:27-05:00

Cyteir Therapeutics Presents Preclinical Data on Use of DNA Repair Modulators for Lymphoid Malignancies at American Society of Hematology Annual Meeting  -- Preclinical data elucidates mechanism of cell death response to selectively target lymphoid cancers --  CAMBRIDGE, Mass. – November 29, 2016 – Cyteir Therapeutics, Inc., a leader in the development of novel therapeutics based on the [...]

Cyteir Therapeutics Presents Preclinical Data on Use of DNA Repair Modulators for Lymphoid Malignancies at American Society of Hematology Annual Meeting2018-03-07T22:47:27-05:00

Cyteir Therapeutics Receives $2M Grant from National Cancer Institute 

2018-03-07T22:48:24-05:00

Cyteir Therapeutics Receives $2M Grant from National Cancer Institute  CAMBRIDGE, Mass. – June 29, 2016 – Cyteir Therapeutics, Inc., a leader in the development of novel therapeutics based on the biology of DNA repair, today announced that it has received a $2 million, two-year grant from the National Cancer Institute (NCI), part of the National Institutes [...]

Cyteir Therapeutics Receives $2M Grant from National Cancer Institute 2018-03-07T22:48:24-05:00
Go to Top